Grant: DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)
McMaster University
$120,000.00
Investigating the role of broadly neutralizing IgA antibodies in response to influenza A virus infection
FY 2025-26
Summary
The flu, caused by influenza A virus, is one of the most common illnesses in the world. Our best way to protect people from the flu is with vaccines, but vaccines are not always effective. This is because flu viruses have a protein on the outside of the virus, called hemagglutinin (HA). When people get a vaccine, their body makes antibodies. Antibodies can recognize parts of the virus, and they bind to the virus and can stop the infection. With the flu vaccine, people make antibodies that recognize the part of HA that can change from season to season. Public health must guess which virus to put in the vaccine. Another strategy is to focus on antibodies that recognize a different part of the HA that does not change. These antibodies can protect against many flu strains. When looking at the antibodies that protect against different strains, most research has looked at one type of antibody, called IgG, that is common in the blood. Another type of antibody, called IgA, is more common in the nose and lungs, which is where we get infected with flu. Scientists have not studied IgA as much because our usual lab animals, like mice, have different immune
systems and do not have the same IgA as humans. To fix this, we are using special mice that have human proteins that interact with IgA, so we can give the mice human IgA. Our goal is to see how IgA antibodies protect against the flu and if they need help from certain immune cells to do their job. To do this, we will give the mice human IgA antibodies and then expose them to the flu to see how well they are protected. We will also test which immune cells help the IgA antibodies fight the flu by removing certain cells and seeing what happens. In the end, we hope to create new IgA antibodies that can be used as a treatment for the flu. By learning more about how these antibodies work, we can make better vaccines and
treatments to help protect people from getting the flu in the future.
Department
Program
DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
559335
Name
Tugg Yona
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
DT1 (Biomedical and/or Clinical Research) CGRS Doctoral
Projecttitle
Investigating the role of broadly neutralizing IgA antibodies in response to influenza A virus infection
Programtype2
Studentship Programs
Orgnameinp2
McMaster University
Cihramount2
$120,000
Cihrequipment2
$0
Programname2
DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)
Keyworddelim
Cd89; Fc Effector Function; Iga; Immune Cell Depletion; Influenza A Virus; Monoclonal Antibodies; Mucosal Immunology; Passive Immunization; Recombinant Antibodies; Transgenic Mice
Abstract
The flu, caused by influenza A virus, is one of the most common illnesses in the world. Our best way to protect people from the flu is with vaccines, but vaccines are not always effective. This is because flu viruses have a protein on the outside of the virus, called hemagglutinin (HA). When people get a vaccine, their body makes antibodies. Antibodies can recognize parts of the virus, and they bind to the virus and can stop the infection. With the flu vaccine, people make antibodies that recognize the part of HA that can change from season to season. Public health must guess which virus to put in the vaccine. Another strategy is to focus on antibodies that recognize a different part of the HA that does not change. These antibodies can protect against many flu strains. When looking at the antibodies that protect against different strains, most research has looked at one type of antibody, called IgG, that is common in the blood. Another type of antibody, called IgA, is more common in the nose and lungs, which is where we get infected with flu. Scientists have not studied IgA as much because our usual lab animals, like mice, have different immune
systems and do not have the same IgA as humans. To fix this, we are using special mice that have human proteins that interact with IgA, so we can give the mice human IgA. Our goal is to see how IgA antibodies protect against the flu and if they need help from certain immune cells to do their job. To do this, we will give the mice human IgA antibodies and then expose them to the flu to see how well they are protected. We will also test which immune cells help the IgA antibodies fight the flu by removing certain cells and seeing what happens. In the end, we hope to create new IgA antibodies that can be used as a treatment for the flu. By learning more about how these antibodies work, we can make better vaccines and
treatments to help protect people from getting the flu in the future.
Competitiondate
202511
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Tugg, Yona
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $120,000~ $0~